Log In Get Started
Press Releases May 28, 2026 08:30 AM

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference

Vor Bio to present corporate update at Jefferies Global Healthcare Conference amid Phase 3 clinical advancement

By Sofia Navarro VOR

Vor Bio, a clinical-stage biotechnology company focused on autoimmune diseases, will provide a corporate update at the 2026 Jefferies Global Healthcare Conference. The presentation will highlight progress on telitacicept, their novel dual-target fusion protein currently in Phase 3 clinical development.

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
VOR

Key Points

  • Vor Bio is advancing telitacicept through Phase 3 clinical trials targeting autoantibody-driven diseases.
  • The company will participate in a widely followed healthcare conference, increasing visibility with investors.
  • Telitacicept’s development could impact the biotechnology and healthcare sectors, especially autoimmune therapeutic markets.

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY.

Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET

A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.


Risks

  • Clinical trial outcomes for telitacicept remain uncertain and could impact commercialization potential.
  • Regulatory approvals are required before telitacicept can reach the market, posing a significant hurdle.
  • Competition in autoimmune disease treatments may affect Vor Bio’s market share and growth prospects.

More from Press Releases

Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026